To: Board of Supervisors
From: Anna Roth, Health Services Director
Report Title: Amendment #76-752-1 with Roche Diagnostics Corporation
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Health Services Director, or designee, to execute on behalf of the County Contract Amendment #76-752-1 with Roche Diagnostics Corporation, a corporation, effective February 27, 2024, to amend Contract #76-752, to increase the payment limit by $1,046,875, from $1,530,425 to a new payment limit of $2,577,300, and to extend the termination date from August 10, 2026 to December 31, 2032, for the purchase of a cobas5800 analyzer used for patient specimen testing, including supplies, software, and service, for the Contra Costa Regional Medical Center (CCRMC) and Contra Costa Health Centers.
FISCAL IMPACT:
Approval of this amendment will result in additional annual expenditures of up to $1,046,875 and will be funded as budgeted by the department, by 100% by Hospital Enterprise Fund I.
BACKGROUND:
This contract amendment meets the needs of CCRMC and its health centers, allowing the trade-in of its existing Roche cobas6800 System for the Roche cobas5800 System, aiding in the automation, integration, consolidation, and standardization of high-volume and molecular testing such as Covid-19 and influenza and allows in-house testing. The Roche cobas5800 System includes ancillary test equipment, reagents, and supplies for CCRMC clinical laboratories and pathology to process, test, and analyze patient specimens.
CCRMC has been using Roche products since 2010. On December 21, 2021, the Board of Supervisors approved Contract #76-752 with Roche Diagnostics Corporation, in the amount not to exceed $1,530,425, for the purchase of a Roche cobas6800 fully automated patient specimen testing system for the period August 11, 2021, through August 10, 2026.
Under this contract amendment, CCRMC will trade in the cobas6800 (purchased under the Roche Diagnostics Corporation Master Agreement County Contract #76-752) and upgrade its current testing platform to the cobas5800 analyzer, which includes specifications required by the Centers for Medicare & Medicaid Services to meet Clinical Laboratory Improvement Amendments and Federal Drug Administration accreditation requirements. The cobas5800 offers a compact, fully automated molecular system that aids in high demands and streamlines the process to a single platform, including preventative maintenance, real-time support, and on-site service.
Approval of Contract Amendment #76-752-1 allows the contractor to provide services through December 31, 2032.
CONSEQUENCE OF NEGATIVE ACTION:
If this amendment is not approved, CCRMC can't trade in its existing test equipment that does not allow for rapid testing once a current batch of samples is loaded, creating several workflow challenges and bottlenecks in patient and employee testing.